Amprenavir (Agenerase): Research
- Dosing Agenerase + Kaletra -- Trying to Juggle, Walk and Chew Gum All at the Same Time (March/April 2004)
A study presented at CROI 2004 bolsters support for the use of therapeutic drug monitoring to customize dosing.
In Positively Aware, from Test Positive Aware Network
- Using Genotypic Inhibitory Quotient to Measure Response to Boosted-Amprenavir Regimen (July 15, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- GW433908 in ART-Naive Subjects: Absence of Resistance at 48 Weeks With Boosted Regimen and APV-Like Resistance Profile With Unboosted Regimen (February 11, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Fosamprenavir Enters the Home Stretch (December 2002)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Research From the 42nd ICAAC: Resistance Tests Compared; Amprenavir Is Guinea Pig (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- A Population Based-Analysis of Amprenavir Trough Concentrations Assessed in the Course of Therapeutic Drug Monitoring (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from TheBodyPRO.com
- Efficacy and Safety of Amprenavir/Ritonavir 600/100 mg BID Compared to APV 1,200 mg BID in ART-Experienced and Naive Subjects: ESS40011 (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Preliminary Results of Intensification Therapy With Amprenavir/Ritonavir in Two Different Doses: 1,200/200 QD vs. 600/100 BID in Heavily Pretreated Patients Failing HAART (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Abacavir/Lamivudine in Combination With Efavirenz, Amprenavir/Ritonavir or Stavudine: ESS40001 (CLASS) Preliminary 48-Week Results (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Potency and Tolerability of Once-a-Day, Directly Observed Therapy for Inner-City, Minority Patients (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Decreased Plasma Concentrations of Amprenavir and Lopinavir in HIV Patients on This Combination (July 8, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- A New Look at Liver Toxicity Development During Antiretroviral Therapy Containing Protease Inhibitors in Patients With HIV (March 11, 2002)
To read PDF, click here.
In STEP Ezine, from Seattle Treatment Education Project
On TheBodyPRO.com
- Amprenavir and Lipodystrophy (March 2002)
In Project Inform Perspective, from Project Inform
- An Assessment of Plasma Amprenavir (APV) Pharmacokinetics (PK) Following Administration of Two GW433908 (908) and Ritonavir (RTV) Regimens in Combination With Efavirenz (EFV) in Healthy Adult Subjects (APV10010) (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Molecular Mechanism of I50V, I54L and I54M Resistance to Amprenavir and Other HIV-1 Protease Inhibitors (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- In Vitro Model for Antiviral Activity for Amprenavir (APV)/Ritonavir (RTV) (December 19, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Efficacy, Safety and Amprenavir: Pharmacokinetic Responses of Twice-Daily APV and Ritonavir Regimens in HIV-1 Infected Treatment-Experienced Adults for 48 Weeks (ESS40006) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Impact on Fitness Conferred by Amprenavir Resistance Mutations (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Variations in HIV-1 Gag p6 Contribute to the Amprenavir-Specific Protease I50V Resistance Pathway (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Amprenavir (APV) Plasma and Intracellular Concentrations When Co-Administered With Ritonavir (RTV) in Twice- and Once-Daily Regimens in HIV-Infected Patients (December 16, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Novel Resistance Pattern Suggests Amprenavir May Be Unique After All (November 2001)
In HEPP News, from Brown Medical School
|
Advertisement
|
Email
Glossary
